Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than HER2 or downstream signaling pathways.Experimental Design:We carried out this multicenter, prospective, case-control study to demonstrate the negative predictive impact of a panel of candidate genomic alterations (AMNESIA panel), includingEGFR/MET/KRAS/PI3K/PTENmutations andEGFR/MET/KRASamplifications. Hypothesizing a prevalence of candidate alterations of 30% and 0% in resistant and sensitive HER2-positive patients, respectively, 20 patients per group were needed.Results:AMNESIA panel alterations were significantly more frequent in resistant (11 of 20, 55%) as compared with sensitive (0% of 17) patients (P< 0.001), and in HER2 IHC 2+(7 of 13, 53.8%) than 3+(4 of 24, 16.7%) tumors (P= 0.028). Patients with tumors bearing no candidate alterations had a significantly longer median progression-free [5.2 vs. 2.6 months; HR, 0.34; 95% confidence interval (CI), 0.07-0.48;P= 0.001] and overall survival (16.1 vs. 7.6 months; HR, 0.38; 95% CI, 0.09-0.75;P= 0.015). The predictive accuracy of the AMNESIA panel and HER2 IHC was 76% and 65%, respectively. The predictive accuracy of the combined evaluation of the AMNESIA panel and HER2 IHC was 84%.Conclusions:Our panel of candidate genomic alterations may be clinically useful to predict primary resistance to trastuzumab in patients with HER2-positive metastatic gastric cancer and should be further validated with the aim of molecularly stratifying HER2-addicted cancers for the development of novel treatment strategies.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Corso, Simona;Aprile, Giuseppe;Corallo, Salvatore;Giordano, Silvia;
2018-01-01

Abstract

Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than HER2 or downstream signaling pathways.Experimental Design:We carried out this multicenter, prospective, case-control study to demonstrate the negative predictive impact of a panel of candidate genomic alterations (AMNESIA panel), includingEGFR/MET/KRAS/PI3K/PTENmutations andEGFR/MET/KRASamplifications. Hypothesizing a prevalence of candidate alterations of 30% and 0% in resistant and sensitive HER2-positive patients, respectively, 20 patients per group were needed.Results:AMNESIA panel alterations were significantly more frequent in resistant (11 of 20, 55%) as compared with sensitive (0% of 17) patients (P< 0.001), and in HER2 IHC 2+(7 of 13, 53.8%) than 3+(4 of 24, 16.7%) tumors (P= 0.028). Patients with tumors bearing no candidate alterations had a significantly longer median progression-free [5.2 vs. 2.6 months; HR, 0.34; 95% confidence interval (CI), 0.07-0.48;P= 0.001] and overall survival (16.1 vs. 7.6 months; HR, 0.38; 95% CI, 0.09-0.75;P= 0.015). The predictive accuracy of the AMNESIA panel and HER2 IHC was 76% and 65%, respectively. The predictive accuracy of the combined evaluation of the AMNESIA panel and HER2 IHC was 84%.Conclusions:Our panel of candidate genomic alterations may be clinically useful to predict primary resistance to trastuzumab in patients with HER2-positive metastatic gastric cancer and should be further validated with the aim of molecularly stratifying HER2-addicted cancers for the development of novel treatment strategies.
2018
24
5
1082
1089
http://clincancerres.aacrjournals.org/content/early/2018/01/24/1078-0432.CCR-17-2781.long
gastric cancer, primary resistance, trastuzumab
Pietrantonio, Filippo; Fucà, Giovanni; Morano, Federica; Gloghini, Annunziata; Corso, Simona; Aprile, Giuseppe; Perrone, Federica; De Vita, Ferdinando; Tamborini, Elena; Tomasello, Gianluca; Gualeni, Ambra Vittoria; Ongaro, Elena; Busico, Adele; Giommoni, Elisa; Volpi, Chiara Costanza; Laterza, Maria Maddalena; Corallo, Salvatore; Prisciandaro, Michele; Antista, Maria; Pellegrinelli, Alessandro; Castagnoli, Lorenzo; Pupa, Serenella M; Pruneri, Giancarlo; de Braud, Filippo; Giordano, Silvia; Cremolini, Chiara; Di Bartolomeo, Maria
File in questo prodotto:
File Dimensione Formato  
2017_Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients the AMNESIA Case-Control Study.pdf

Accesso riservato

Descrizione: Clin Canc Res 2017_RISERVATO
Tipo di file: PDF EDITORIALE
Dimensione 394.78 kB
Formato Adobe PDF
394.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Clin Canc Res_2017_APERTO.pdf

Open Access dal 07/12/2018

Descrizione: Clin Canc Res 2017_APERTO
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 525.31 kB
Formato Adobe PDF
525.31 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1660557
Citazioni
  • ???jsp.display-item.citation.pmc??? 42
  • Scopus 69
  • ???jsp.display-item.citation.isi??? 68
social impact